Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. (IDRA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
idra · pe ratio · data through Dec 31, 2022
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for Idera Pharmaceuticals, Inc. (IDRA) measures how much investors pay for each dollar of the company's trailing earnings. IDRA's current PE ratio of N/A is calculated by dividing its stock price of $0.42 by its TTM earnings per share of -$7.17.
Source: FMP · /ratios-ttm · /analyst-estimates · 2022-12-31
PE Ratio History
2003 – 2022 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
Historical PE Range
Past 3 fiscal years · Front-end computedMinQ1 · 25%0.9x
MedianQ3 · 75%6.8x
Max
At N/A, IDRA's current P/E is lower than in 0% of its annual fiscal year readings over the past 3 years — historically low.
Percentile calculated from annual fiscal year data points, not by trading day. Years where PE ≤ 0 or > 9,999 are excluded.
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Idera Pharmaceuticals, Inc.You IDRA | — | N/A | — | -$7.17 |
 Allakos Inc. ALLK | $30M | N/A | — | -$1.30 |
 Angion Biomedica Corp. ANGN | $30M | N/A | — | -$2.58 |
 AnPac Bio-Medical Science Co., Ltd. ANPC | $27M | N/A | — | -$54.18 |
 Freeline Therapeutics Holdings plc FRLN | $28M | N/A | — | -$22.52 |
 Gemini Therapeutics, Inc. GMTX | $25M | N/A | — | — |
 Liminal BioSciences Inc. LMNL | $28M | N/A | — | -$341.80 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2022-12-31Latest FY2022 | — | $-7.17 | — | |
2021-12-31 FY2021 | 0.02x | $31.55 | — | |
2020-12-31 FY2020 | — | $-56.64 | — | |
2019-12-31 FY2019 | — | $-50.36 | — | |
2018-12-31 FY2018 | — | $-38.26 | — | |
2017-12-31 FY2017 | — | $-57.03 | — | |
2016-12-31 FY2016 | — | $-40.92 | — | |
2015-12-31 FY2015 | — | $-57.38 | — | |
2014-12-31 FY2014 | — | $-63.45 | — | |
2013-12-31 FY2013 | — | $-56.46 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Idera Pharmaceuticals, Inc. (IDRA) measures how much investors pay for each dollar of the company's trailing earnings. IDRA's current PE ratio of N/A is calculated by dividing its stock price of $0.42 by its TTM earnings per share of -$7.17.
Frequently asked questions
IDRA pe ratio · 6 questionsIDRA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.42 and TTM EPS of -$7.17. Data sourced from Financial Modeling Prep via IDRA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Idera Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09